BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30673070)

  • 1. Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia.
    Teran VA; Wilson BB; Guffey DJ
    JAMA Dermatol; 2019 Mar; 155(3):389-391. PubMed ID: 30673070
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Imagawa J
    Leuk Lymphoma; 2018 Dec; 59(12):3013-3015. PubMed ID: 29616847
    [No Abstract]   [Full Text] [Related]  

  • 3. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Promyelocytic Leukemia With Sudden Vision Loss.
    Hua HU; Rayess N; Moshfeghi AA
    JAMA Ophthalmol; 2020 Feb; 138(2):206-207. PubMed ID: 31804661
    [No Abstract]   [Full Text] [Related]  

  • 5. Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help?
    Buhtoiarov IN
    J Pediatr Hematol Oncol; 2021 May; 43(4):158. PubMed ID: 33625082
    [No Abstract]   [Full Text] [Related]  

  • 6. Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Kulkarni UP; Selvarajan S; Lionel S; Prakash MA; Palani HK; Balasundaram N; Venkataraman A; Korula A; Devasia AJ; Fouzia NA; Janet NB; Nair SC; Abraham A; Mani T; Lakshmanan J; Arunachalam AK; Balasubramanian P; George B; Mathews V
    Blood Cancer J; 2022 Jan; 12(1):22. PubMed ID: 35102152
    [No Abstract]   [Full Text] [Related]  

  • 7. Differentiation syndrome in acute promyelocytic leukaemia.
    Stahl M; Tallman MS
    Br J Haematol; 2019 Oct; 187(2):157-162. PubMed ID: 31410848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen.
    Khosla H; Jain A; Tatawadiya S; Prasad P; Nagpal K; Chaudhry S; Sharma M; Gupta DK; Saluja S; Jain A
    Blood Cells Mol Dis; 2020 Nov; 85():102476. PubMed ID: 32688220
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
    Strocchio L; Gurnari C; Santoro N; Putti MC; Micalizzi C; Zecca M; Cuccurullo R; Girardi K; Diverio D; Testi AM; Lo-Coco F; Locatelli F
    Br J Haematol; 2019 Apr; 185(2):360-363. PubMed ID: 30028005
    [No Abstract]   [Full Text] [Related]  

  • 11. Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
    Jiang W; Lee SH
    Blood; 2018 Nov; 132(21):2314. PubMed ID: 30467190
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute Promyelocytic Leukemia.
    Winkler C
    N Engl J Med; 2024 May; 390(17):e42. PubMed ID: 38683728
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia.
    Yang CL; Shen K; Huang J
    Chin Med J (Engl); 2018 Oct; 131(19):2386-2387. PubMed ID: 30246736
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    Garcia Spezza E; Brethon B; Petit A; Mazingue F; Gandemer V; Boissel N; Carausu L; Reguerre Y; Leverger G; Ducassou S
    Br J Haematol; 2020 Jan; 188(1):170-173. PubMed ID: 31808943
    [No Abstract]   [Full Text] [Related]  

  • 17. Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.
    Rhee JY; Tremblay D; Chan AM; Tallman MS; Mascarenhas J
    Blood Adv; 2019 Jun; 3(12):1854-1857. PubMed ID: 31213431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
    Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
    Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic and all-
    Levis M
    Haematologica; 2021 Dec; 106(12):3031-3032. PubMed ID: 34047181
    [No Abstract]   [Full Text] [Related]  

  • 20. A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
    Pemmaraju N
    Cancer; 2021 Aug; 127(16):2867-2869. PubMed ID: 33891316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.